Sign In
Buy CLLS
$3.09
-0.290 (-8.58%)
At Close: Jun 03, 2026
Cellectis (NASDAQ:CLLS) Share Price Crosses Below 50-Day Moving Average – What’s Next?
04:12am, Saturday, 10'th Jan 2026
Shares of Cellectis S.A. (NASDAQ: CLLS - Get Free Report) passed below its 50 day moving average during trading on Friday. The stock has a 50 day moving average of $4.44 and traded as low as $4.36. Ce
Monthly information on share capital and company voting rights
04:30pm, Monday, 05'th Jan 2026
(Article 223-16 of General Regulation of the French financial markets authority) (Article 223-16 of General Regulation of the French financial markets authority)
Cellectis (NASDAQ:CLLS) Stock Crosses Above Fifty Day Moving Average – Should You Sell?
04:38am, Saturday, 20'th Dec 2025
Shares of Cellectis S.A. (NASDAQ: CLLS - Get Free Report) passed above its 50 day moving average during trading on Friday. The stock has a 50 day moving average of $4.17 and traded as high as $4.46. C
Allogene Arbitration Victory Pressures Cellectis Shares Tuesday
01:09pm, Tuesday, 16'th Dec 2025
Shares of Cellectis S.A. (NASDAQ: CLLS) tanked on Tuesday after Allogene Therapeutics Inc. (NASDAQ: ALLO) cited a favorable arbitration outcome for partner Servier in its dispute with Cellectis relate
Allogene Therapeutics Reports Favorable Result for Servier in Arbitration with Cellectis
05:39pm, Monday, 15'th Dec 2025
Arbitration Ruling Reaffirms Allogene's Full Control of Cemacabtagene Ansegedleucel (Cema-Cel) Decision Reconfirms Allogene's Expanded Sub-License Covering EU and UK Rights with Options for Japan and
Cellectis Announces Arbitral Decision in Dispute with Servier
04:51pm, Monday, 15'th Dec 2025
NEW YORK, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS – NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform t
Cellectis' Allogeneic CAR-T Potential Still Justifies A 'Buy'
09:31pm, Thursday, 11'th Dec 2025
CELLS develops off-the-shelf TALEN-edited CAR-T therapies. Its main in-house asset is lasme-cel for r/r B-ALL and eti-cel for r/r B-cell NHL. Early data show that lasme-cel reached impressive ORRs in
ASH 2025: Cellectis Presents Development Plan to Further Enhance High Response Rate Observed for Eti-cel in r/r NHL
01:30am, Monday, 08'th Dec 2025
NEW YORK, Dec. 08, 2025 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS – NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform t
Monthly information on share capital and company voting rights
04:30pm, Wednesday, 03'rd Dec 2025
(Article 223-16 of General Regulation of the French financial markets authority) (Article 223-16 of General Regulation of the French financial markets authority)
NEW YORK, Nov. 19, 2025 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS – NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform t
Cellectis Reports Third Quarter 2025 Financial Results and Provides Business Update
04:30pm, Friday, 07'th Nov 2025
Presented data underscore the potential of lasme-cel (UCART22) and eti-cel (UCART20x22) to improve outcomes in r/r B-ALL and r/r NHL: Lasme-cel in r/r B-ALL (BALLI-01) ORR of 68% with lasme-cel Proces
Cellectis to Present a Development Update for eti-cel at ASH 2025
09:15am, Monday, 03'rd Nov 2025
NEW YORK, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to
Cellectis to Report Third Quarter Financial Results on November 7, 2025
04:30pm, Friday, 31'st Oct 2025
NEW YORK, Oct. 31, 2025 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS- NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to d
○ Efficacité: taux de réponse global (ORR) de 68 % avec le Process 2 de lasmé-cel (P2) (n=22); 83 % à la dose recommandée de Phase 2 (RP2D, n=12); et 100 % dans la population cible de Phase 2 (
Cellectis' R&D Day Highlights Lasme-cel's Potential to Address Significant Unmet Need for Patients with r/r B-ALL
03:19pm, Thursday, 16'th Oct 2025
○ Efficacy: ORR of 68% with lasme-cel Process 2 (n=22), 83% at RP2D (n=12) and 100% in the target Phase 2 population (n=9)
